CORT News and Press, Corcept Therapeutics Incorporated From 06/08/23

2023-06-08 08:33:03 ET Summary Corcept Therapeutics' stock is trading back at FY'22 range after a snapback rally leading into Q2 FY'23. The company is allocating capital to its clinical programs, but returns on these investments haven't beat the hurdle to date, leading to economic...

2023-05-03 23:43:04 ET Corcept Therapeutics Incorporated (CORT) Q1 2023 Earnings Conference Call May 3, 2023 17:00 ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer ...

2023-05-03 16:15:53 ET Corcept Therapeutics press release ( NASDAQ: CORT ): Q1 GAAP EPS of $0.14 misses by $0.05 . Revenue of $105.7M (+12.8% Y/Y) beats by $0.79M . Cash and investments of $465.1 million as of March 31, 2023 Purchase of 6.6 million sh...

MENLO PARK, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hor...

2023-05-02 17:35:56 ET Major earnings expected after the bell on Wednesday include: QUALCOMM Incorporated ( QCOM ) Realty Income corporation ( O ) MercadoLibre ( MELI ) ETSY ( ETSY ) Fastly ( FSLY ) For further details see: Notable earning...

MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the h...

MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the h...

MENLO PARK, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the h...

2023-03-28 06:24:51 ET Summary Shares have lost over half their value during the past year. Commercial momentum appears to be building with management guiding for break-even cash flow by the end of 2023. Keveyis is facing generic competition in PPP and Recorlev is still in the...

2023-03-06 09:28:28 ET Corcept Therapeutics ( NASDAQ: CORT ), the maker of Cushing’s syndrome therapy Korlym added 10% pre-market Monday after the company announced a tender offer to buy back up to 7.5M shares of its common stock. The company said the share repu...